Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression?

Trends in Molecular Medicine

Volumn 14, Issue 3, 2008, Pages 103-108

  Small, David H ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; HUMAN; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DEMENTIA; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NERVE NET; NEURONAL PLASTICITY;

EID: 40649095625     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.12.006     Document Type: Article

References (44)

1. Storey E., et al. The neuropsychological diagnosis of Alzheimer's disease. J. Alzheimers Dis. 3 (2001) 261-285
2. Probst A., et al. Alzheimer's disease: a description of the structural lesions. Brain Pathol. 1 (1991) 229-239
3. Braak H., and Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16 (1995) 271-278
4. Nunan J., and Small D.H. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 483 (2000) 6-10
5. Walsh D.M., and Selkoe D.J. A beta oligomers - a decade of discovery. J. Neurochem. 101 (2007) 1172-1184
6. Small D.H., et al. Alzheimer's disease and Aβ toxicity: from top to bottom. Nat. Rev. Neurosci. 2 (2001) 595-598
7. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3 (2002) 862-872
8. Duchen M.R. Mitochondria and calcium: from cell signalling to cell death. J. Physiol. 529 (2000) 57-68
9. Romito-DiGiacomo R.R., et al. Effects of Alzheimer's disease on different cortical layers: the role of intrinsic differences in Aβ susceptibility. J. Neurosci. 27 (2007) 8496-8504
10. Cecchi C., et al. Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates. J. Cell Sci. 118 (2005) 3459-3470
11. Palop J.J., et al. A network dysfunction perspective on neurodegenerative diseases. Nature 443 (2006) 768-773
12. Terry R.D. Cell death or synaptic loss in Alzheimer disease. J. Neuropathol. Exp. Neurol. 59 (2000) 1118-1119
13. Hsieh H., et al. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52 (2006) 831-843
14. Yuste R., and Bonhoeffer T. Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu. Rev. Neurosci. 24 (2001) 1071-1089
15. Hopfield J.J. Neural networks and physical systems with emergent collective computational abilities. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 2554-2558
16. Ruppin E., and Reggia J.A. A neural model of memory impairment in diffuse cerebral atrophy. Br. J. Psychiatry 166 (1995) 19-28
17. Turrigiano G.G. Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Trends Neurosci. 22 (1999) 221-227
18. Turrigiano G.G., and Nelson S.B. Homeostatic plasticity in the developing nervous system. Nat. Rev. Neurosci. 5 (2004) 97-107
19. Davis G.W., and Goodman C.S. Genetic analysis of synaptic development and plasticity: homeostatic regulation of synaptic efficacy. Curr. Opin. Neurobiol. 8 (1998) 149-156
20. Davis G.W., and Goodman C.S. Synapse-specific control of synaptic efficacy at the terminals of a single neuron. Nature 392 (1998) 82-86
21. Rutherford L.C., et al. BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses. Neuron 21 (1998) 521-530
22. Rutherford L.C., et al. Brain-derived neurotrophic factor mediates the activity-dependent regulation of inhibition in neocortical cultures. J. Neurosci. 17 (1997) 4527-4535
23. Stellwagen D., and Malenka R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 440 (2006) 1054-1059
24. Stellwagen D., et al. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J. Neurosci. 25 (2005) 3219-3228
25. Palop J.J., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55 (2007) 697-711
26. Small D.H. Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease?. Trends Neurosci. 27 (2004) 245-249
27. DeKosky S.T., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 51 (2002) 145-155
28. Luth H.J., et al. Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. Brain Res. 977 (2003) 16-22
29. Saez-Valero J., et al. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J. Neurochem. 72 (1999) 1600-1608
30. Dineley K.T., et al. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277 (2002) 22768-22780
31. Hu L., et al. The impact of Aβ-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience 121 (2003) 421-432
32. Fodero L.R., et al. Altered glycosylation of acetylcholinesterase in APP(SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. J. Neurochem. 81 (2002) 441-448
33. Tong L., et al. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 24 (2004) 6799-6809
34. Garzon D.J., and Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J. Neurosci. 27 (2007) 2628-2635
35. Peng S., et al. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 93 (2005) 1412-1421
36. Jia J.P., et al. Cerebrospinal fluid tau, Aβ1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci. Lett. 383 (2005) 12-16
37. Ho G.J., et al. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr. Drug Targets Inflamm. Allergy 4 (2005) 247-256
38. Quadros A., et al. Increased TNFα production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice. Neurosci. Lett. 353 (2003) 66-68
39. Mattson M.P., et al. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12 (1992) 376-389
40. Marx J. Fresh evidence points to an old suspect: calcium. Science 318 (2007) 384-385
41. Morrison J.H., and Hof P.R. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog. Brain Res. 136 (2002) 467-486
42. Bartus R.T., et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
43. Golde T.E. Disease-modifying therapy for AD?. J. Neurochem. 99 (2006) 689-707
44. Zhao L., et al. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer's disease. Nat. Neurosci. 9 (2006) 234-242